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ABSTRACT 
 
Genetic factors have been implicated in the pathogenesis of osteoporosis, a common 
disorder in primary biliary cirrhosis (PBC). Estrogen receptor-alpha gene (ER-), 
vitamin-D-receptor gene (VDR) and IL-1-receptor-antagonist gene (IL-1RN) are all 
attractive candidates for osteoporosis susceptibility. Furthermore insulin-like growth 
factor-I (IGF-I) gene microsatellite repeat polymorphism was found to be associated with 
osteoporosis in some studies and collagen-I1 (COLIA1) Sp1 s allele was associated 
with lower bone mineral density (BMD) in one study in PBC. IGF-I treatment restored 
osteopenia and reduced fibrogenesis in experimental cirrhosis. In this study we 
summarize our results on polymorphisms of the above genes and bone disease in 
Hungarian PBC patients. 
Patients and methods: 70 female patients with PBC were enrolled (age:57.6yrs, 
range:37-76yrs, each AMA-M2 positive, stage II-IV). 139 age-matched female subjects 
served as controls (age: 55.9 yrs, range:43-72 yrs). COLIA1 Sp1 and IGF-I microsatellite 
polymorphisms were determined by PCR in all patients and controls. VDR BsmI, IL-
1RN variable-number tandem repeat (VNTR) and ER- PvuII and XbaI polymorphisms 
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were detected in 33 patients and controls. BMD was measured by dual energy x-ray 
absorptiometry (Lunar,Prodigy,USA) in lumbar spine (LS) and femoral neck (FN).  
Results: There was no difference in IGF-I microsatellite repeat polymorphism 
(192/192=34.2%, 194/192=28.6%, other=37.2%) and COLIA1 Sp1 polymorphism 
(SS=72.9%, Ss=22.8% and ss=4.3%) and IL-1 VNTR polymorphism between PBC 
patients and controls, however, the COLIA1 Sp1 s allele was significantly less frequent 
in patients with PBC (p=0.038). The genotype frequency of VDR BsmI (BB=57.5%, 
Bb=33.3%, bb=9.1%, p=0.01) and ER-a PvuII (PP=18.2%, Pp=75.6%, pp=6.2%, 
p=0.03) and XbaI (XX=9.1%, Xx=90.9%, xx=0%, p=0.0003) of the patients was 
different from that of the control group, with higher frequency of the BB, Pp and Xx 
genotypes in PBC. Osteoporosis (t score<-2.5) was detected in 22 patients (31.4%). 
Osteoporotic patients were elder and had longer disease history (p=0.01 for both). An 
association was found between the IGF-I genotypes and ODM data, the 192/192 
genotype was associated with higher FN Z-score compared to other genotypes (p=0.036).  
Conclusions: In contrast to previous studies the COLIA1 Sp1 s allele was less 
frequent in patients with PBC, and its presence was not associated with BMD. We 
confirmed previous findings on higher frequency of VDR BsmI BB genotype in patients 
with PBC. The ER-α PvuII and XbaI Pp and Xx genotypes were more frequent in PBC 
patients, while IL-1RN VNTR and IGF-I microsatellite repeat polymorphism was not 
different. Since IGF-I polymorphism was associated to BMD, it may be hypothesized 
that not COLIA1 but IGF-I together with other genetic and environmental factors may be 
involved in the complex regulation of BMD in PBC.  
 
Keywords: Primary biliary cirrhosis, hepatic osteopathy, gene polymorphisms, estrogen 
receptor gene, vitamin D receptor gene, IL-1 receptor antagonist gene, COLIA1, IGF-I, 
microsatellite repeat polymorphism. 
 
 
INTRODUCTION 
  
Primary biliary cirrhosis (PBC) is a chronic cholestatic disease believed to be of 
autoimmune origin, which is characterized by the inflammation of the small bile ducts, 
affecting middle age women [1]. Osteoporosis (OP) is a common complication in primary 
biliary cirrhosis (PBC), even in the absence of biochemical hyperbilirubinaemia. It is a major 
source of morbidity and mortality [2,3 ,4].  
The pathogenesis of bone disease in PBC is not fully understood. Numerous factors may 
be involved in the pathogenesis, such as immobility, poor nutrition, disturbances in hormonal 
status, immunological alterations, as well as risk factors commonly associated with primary 
osteoporosis (postmenopausal status, cigarette smoking, and alcohol consumption). Possible 
mechanisms include Ca and vitamin D malabsorption as a consequence to bile salt 
deficiency, vitamin K deficiency, altered parathyroid function [5,6,7]. Both low and high 
bone turnover states have been reported in PBC [8,9,10]. Recent study by our group showed 
high osteoprotegerin and low RANKL level in patients with PBC that might represent a 
compensatory mechanism to negative balance of bone remodeling [8].  
Bone mass is partially determined by genetic factors and which may account for up to 
75-80% of the variability in BMD in healthy women [11]. Twins studies and segregation 
analysis in normal families have suggested polygenic regulation of BMD [11,12]. Several 
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candidate genes involved in the control of bone formation have been identified. The best 
characterized genetic association is the relationship between Vitamin D receptor (VDR) 
allelic polymorphisms and BMD in prae- and postmenopausal women [13,14,15,16] with or 
without hormone replacement therapy [17]. The presence of BB genotype or B allele was 
associated with greater risk to develop osteoporosis [14, 15]. 
 This association was not confirmed in some studies [18,19]. Likewise, data in patients 
with PBC are conflicting. VDR genotypes are associated with PBC, independent of changes 
of BMD [20,21]. However, they may explain the role of hormonal influence in the 
development of hepatic osteopathy in PBC [22]. Another polymorphisms related to 
osteoporosis is located in the first intron of the collagen type 1α1 (COLIA1) gene Sp1 
[23,24,25,26]. The s (T) allele is associated with increased bone loss and fracture frequency 
and decreased yield threshold in otherwise healthy subjects. The ss genotype was associated 
with a 2-fold increased rate of yearly bone loss and a 5.9-fold elevated risk of bone fractures 
[23,24]. In a meta-analysis of Efstathiadou and colleagues [27] the total average attributable 
fraction of fractures due to the s allele in Europe/U.S. population was estimated as 9.4%. 
Finally, the Ss genotype was associated with reduced yield strength of bone samples 
compared to SS genotypes [28]. In the only study in PBC patients COLIA1 genotype was a 
genetic marker of peak bone mass [29]. Because of the impact of estrogens on bone 
formation the estrogen receptor alpha (ER-α) gene PvuII, XbaI- and (TA)n promoter repeat 
polymorphisms are also of particular interest [30,31,32,33]. In Japanese postmenopausal 
women a strong association between ER-α gene PvuII polymorphism and reduced bone mass 
in the spine was observed [30,34] but data in Caucasians are conflicting [31,32,33,35]. 
Experimental studies support the role of the ER-α gene in the regulation of BMD. In 
transgenic ER knockout mice BMD is 20-25% lower than in normal mice [36]. So far, ER-α 
gene polymorphisms were not studied in patients with PBC. Insulin-like growth factor-I 
(IGF-I) is a ubiquitous polypeptide involved in cell growth and differentiation, stimulation of 
linear growth and proliferation of chondrocytes. It also plays an important role in the 
acquisition of peak bone mineral density (BMD) [37,38,39]. Serum IGF-I levels are 
decreased in chronic liver diseases [40,41,42], but there was no relationship between serum 
IGF-I and BMD. A microsatellite repeat polymorphism located 1kb upstream from the IGF-I 
gene transcript start site appears to exert a genetic control of bone formation, the 192/192 
genotype is associates with lower BMD [37,43]. No data are available on IGF-I microsatellite 
repeat polymorphisms in chronic liver diseases. 
Interleukin-1 receptor antagonist (IL-1Ra) is a competitive inhibitor of IL-1α and β, 
which completely inhibits the stimulatory effects of interleukin-1 (IL-1) on bone resorption in 
vitro [44]. A trend for higher IL-1/IL-1Ra ratio found in osteoporotic women compared with 
healthy age-matched controls [45]. Some, but not all studies reported an association between 
the number of tandem repeats (VNTR) of interleukin-1 receptor antagonist gene (IL-1RN) 
and postmenopausal bone loss in the spine [46,47]. The A2 allele was associated with some 
inflammatory and autoimmune diseases [48,49,50,51]. In this study the polymorphisms of the 
above mentioned genes was investigated in two cohorts of Hungarian PBC patients and 
correlated them with clinical, laboratory and osteodensitometric findings. 
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PATIENTS AND METHODS 
 
Patients 
 
VDR BsmI, ER- α, and IL-1RN VNTR polymorphisms were studied 33 (group 1; mean 
age: 54.7 ± 11.7 yrs; 27 postmenopausal), IGF-I microsatellite repeat and COLIA1 Sp1 
polymorphism in 70 patients (group 2; mean age: 57.6 ± 10.6 yrs; 62 postmenopausal; 
histologic stage: I: 11, II: 31, III: 18, and IV: 10 patients). All patients were female with 
biochemical evidence of cholestasis, consistent histological findings and anti-mitochondrial 
antibody (AMA) M2 positivity. Patients with evidence of extrahepatic cholestasis were 
excluded. All patients received ursodeoxycholic acid (UDCA) as well as 1000 mg Ca and 
individually 1000-3000 IU Vitamin D3 supplementation orally. None of the patients received 
other treatment for osteoporosis. The serum Ca and vitamin D3 values of the patients were in 
the normal range. The clinical data of the PBC patients are summarized in Table 1.  
The onset of the disease was defined as the date of the first documentation of abnormal 
liver function test, the duration of liver disease as the time from disease onset to the date of 
the BMD measurement. For the study of VDR BsmI, ER- α, and IL-1RN VNTR 
polymorphisms 82 age matched, healthy female controls (mean age: 54.1 ± 4.7 yrs, 
postmenopausal: 71/82, 86 %) were selected from a panel undergoing DNA genotyping. 
None of the healthy controls had osteoporosis, 58.5% had osteopenia. We also selected 76 
female subjects with osteoporosis as as “disease” control group (mean age: 56.8 ± 6.1 yrs, 93 
%, 71/76 postmenopausal, weight: 62.1 ± 10.1 height: 160 ± 6.9, BMD LS: 0.847 ± 0.123, Z-
score: -1.627 ± 1.083, T-score: -2.987 ± 0.961, BMD FN: 0.749 ± 0.105 Z-score: -0.721 ± 
0.846, T-score: -1.901 ± 0.962). For the study of IGF-I microsatellite repeat and COLIA1 
Sp1 polymorphism 139 age-matched, healthy females served as controls (mean age: 55.9 ± 
6.8 yrs, postmenopausal: 118/139, 84.9%). 53 control subject had osteopenia (46.1%).  
The studies were approved by the Semmelweis University Regional and Institutional 
Committee of Science and Research Ethics. After written informed consent, all patients and 
controls underwent DNA genotyping and BMD measurements. 
 
 
Methods 
 
Laboratory Determinations 
Serum bilirubin concentration, aspartate-aminotransferase (AST), alanine-amino-
transferase (ALT), alkaline phosphatase (ALP) and albumin activities were measured by 
Olympus AU600 (Olympus Co. Ltd, Shizuoka, Japan) autoanalyser at 37 °C. The enzyme 
activities are expressed in U/L, albumin in g/L and serum bilirubin concentration is given in 
μmol/L. AMA M2 was determined by immunofluorescent method (Binding Site kit, 
Birmingham, UK), vitamin D3 level by RIA (25-OH D3 vitamin kit, Med-elpho Ltd, 
Budapest, Hungary).  
Serum osteocalcin (OC) levels were measured with the N-MID Osteocalcin 
Electrochemiluminescence Immunoassay (ELICA) kit (Roche Diagnostics GmbH, 
Mannheim, Germany). The serum levels of C-terminal cross-linking telopeptide of type I 
Gene Polymorphisms in Primary Biliary Cirrhosis 63
collagen (CTX-I) was determined by the Elecsys β-Crosslaps immunoassay kit (Roche 
Diagnostics GmbH, Mannheim, Germany). Both measurements were performed by Elecsys 
2010 immunoassay system (Hitachi, Tokyo, Japan). 
 
Table 1. The summary of the clinical and laboratory data of PBC patients according to 
the presence of osteoporosis (values are mean ± SD, *p=0.01, #p=0.03, between patients 
with osteoporosis vs. without osteoporosis, in the brackets see normal values.) 
 
 Study 1   Study 2   
 total with 
osteoporosis 
without 
osteoporosis 
total with  
osteoporosis 
Without 
osteoporosis 
Number of 
patients 
33 14 19 70 22 48 
Age (years) 54.7 ± 11.7 58 ± 10* 52 ± 12* 57.6 ± 10.6 60.8 ± 8.8 56.2 ± 11.1# 
Duration of 
the disease 
(years) 
7.8 ± 5.7  9.5 ± 5.1* 5.4 ± 3.3*  6.8 ± 5.5 9.0 ± 6.8 55.8 ± 4.# 
Serum 
bilirubin (0-
20.5 μmol/l) 
31.4 ± 75.6 49.1 ± 112.8 18.5 ± 23.7 29.1 ± 58.2 35.1 ± 93.1 26.2 ± 30.5 
ASAT (1-46 
U/l) 
41.2 ± 23.9 44.9 ± 27.0 38.5 ± 21.7 42.4 ± 21.2 44.6 ± 21.9 41.4 ± 21.1 
ALAT (1-49 
U/l) 
42.3 ± 26.6 45.6 ± 33.6 39.9 ± 20.5 44.9 ± 25.5 48.1 ± 30.2 43.3 ± 23.1 
GGT (9-52 
U/l) 
166.6 ± 146.6 162.7 ± 181.8 169.6± 117.9 205.5 ± 
211.4 
169.4 ± 173.9 223.1 ± 227.3 
ALP (98-290 
U/l) 
496.2 ± 227.3 517.7 ± 214.8 480.4 ± 240.6 551.8 ± 
326.2 
480.2 ± 231.1 586.8 ± 361.1 
Albumin (35-
50 g/L) 
43.4 ± 4.2 42.8 ± 4.5 44.0 ± 4.2 41.7 ± 5.0 42.7 ± 3.9 41.1 ± 5.5 
Ca (2.25-2.61 
mmol/l) 
2.44 ± 0.14 2.45 ± 0.14 2.43 ± 0.14 2.37 ± 0.16 2.43 ± 0.13 2.35 ± 0.17 
P (0.85-1.45 
mmol/l) 
1.11 ± 0.14 1.12 ± 0.14 1.11 ± 0.14 1.09 ± 0.13 1.10 ± 0.14 1.18 ± 0.14 
Vitamin D 
(60-180 
nmol/l) 
151.5 ± 61.6 131.5 ± 40.2 183.6 ± 72.5 146.5 ± 47.4 134.4 ± 30.1 172.3 ± 56.7 
OC (20-48 
ng/ml) 
- - - 22.9 ± 13.5 25.9 ± 17.9 21.1 ± 9.8 
CTX-I (0-320 
pg/ml) 
- - - 329.0 ± 
278.6 
401.1 ± 414.1 283.4 ± 128.3 
 
Genomic DNA Analysis 
Genomic DNA was extracted from peripheral mononuclear cells using DNA isolation-kit 
(NukleoSpin Blood Quickpure, Macherey-Nagel, Düren, Germany) according to the 
description of the manufacturer and amplified by polymerase chain reaction (PCR) with 
sequence-specific primers using a Hybaid Express thermocycler (Teddington, Middlesex, 
UK). PCR products were separated by electrophoresis on 2% agarose gel at 120V for 30 min 
and visualized by ethidium bromide staining if not stated otherwise.  
 
Vitamin D Receptor Genotyping 
A fragment of the vitamin D receptor was amplified by PCR with primers as described 
previously [13]. The amplified DNA was subjected to digestion by BsmI resriction enzyme 
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(65oC, 90 min) with enzyme Bsm1, Hybaid, Teddington, UK) and the fragments were 
separated by gel electrophoresis. The absence or presence of the BsmI restriction site is 
indicated by B (825 bp) or b (650 + 175 bp) respectively. All samples with BB genotype 
were repeatedly digested and analyzed to avoid possibility of enzyme inhibition and the false 
assignment of bb or Bb genotype to truly BB individuals. 
 
Estrogen Receptor Alpha Genotyping 
ER-α genotyping was performed by PCR using previously described primers and 
amplification conditions [30]. For the digestion of ER PCR product enzymes PvuII, XbaI 
(Hybaid, Teddington, UK) were used (37oC 90 min). The genotype assignments were PP, Pp, 
pp for PvuII and XX, Xx, xx for XbaI, with uppercase letters signifying the absence of and 
lower case letters the presence of the restriction site. 
IL-1-RN genotyping 
DNA was subjected to PCR amplification for the 86 bp tandem repeat polymorphism of 
the IL-1RN gene using primers as described [52]. Allele assignments were made in 
accordance with previous reports: allele 1 (A1), 410 bp-four repeats; allele 2 (A2), 240 bp-
two repeats; allele 3 (A3), 500 bp-five repeats; allele 4 (A4),325 bp-three repeats; allele 5 
(A5), 595 bp-six repeats. 
 
IGF-I Genotyping 
The PCR was performed with primers and amplification conditions as described 
previously [53], to amplify a polymorphic microsatellite composed of variable cytosine-
adenine (CA) repeats, situated 1kb upstream from the transcription start site of the IGF-I 
gene. The forward primer was radiolabeled with 32P using T4 polynucleotid kinase 
(Invitrogen Corp., Carlsbad, CA, USA). Radiolabeled PCR products were screened for length 
variation by a 6.5% polyacrilamide gel electrophoresis at 70 watts for 165 min. 
Autoradiographs were exposed for 4-12 h in cassettes without intensifying screens. 
Genotypes were scored by two independent investigators. Allele assignments were made 
according to the size of the CA repeat.  
 
COLIA1 genotyping 
COLIA1 Sp1 genotypes were determined by PCR using previously described primers 
and amplification conditions using [54]. The amplified DNA was subjected to digestion by 
BSA restriction enzyme (37oC for 30 h, New England BioLabs GmbH, Frankfurt Germany) 
and the fragments were separated by gel electrophoresis (2% agarose at 120V for 30 min) and 
visualized by ethidium bromide staining. The alleles were assigned as “S” (G) or “s” (T) [54]. 
 
 
BMD Assessment  
 
Bone density was measured at the lumbar spine (L2-4) and at the femoral neck (FN) by 
dual-energy X-ray absorptiometry (Lunar Prodigy, Lunar corp., Madison, WI, USA). BMD 
was expressed as areal density m grams per square centimeter, as well as in t-scores 
(difference from the mean BMD value of healthy young people divided by its standard 
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deviation) and z-scores (difference from the mean BMD value of age-matched people divided 
by its standard deviation). Established osteoporosis was diagnosed if the BMD t-score value 
was below –2.5 at either position [55]. 
 
 
Statistical Analysis 
 
Shapiro Wilk’s W test was used to test normality. To test the differences between 
genotype / allele frequencies of the cohort and controls and between subgroups of the patients 
Chi square analysis or Fischer exact with Yates correction test was computed. To test the 
differences in clinical data between osteoporotic and non-porotic patients as well as between 
patients and controls t-test with separate variance estimates and in study 2 Mann-Whitney U 
test was used. The correlation between laboratory findings and BMD was tested by using 
Spearman Rank Order Correlation. The association between genotype or allele frequencies 
and BMD was tested by using ANOVA and post hoc Scheffe analysis. For the purposes of 
comparison the patients were considered osteoporotic if they fulfilled t-score criteria at either 
lumbar spine or femoral neck. For the statistical analysis Statistica for Windows 6.0 (StatSoft 
Inc., OK, USA) was used. A p value <0.05 was considered significant. 
 
 
RESULTS 
 
Osteoporosis (OP) was detected in 14 (42.4%) and 22 patients (31.4%) in groups 1 and 2, 
respectively. Each or them was in the postmenopause and they were approximately 5-years 
older and had a longer disease history compared to patients without OP (p=0.01 and p=0.03, 
for both). In group 1 OP was associated with increased fracture frequency (at least one 
fracture in 6/14 OP patients vs. 1/19 non-OP, p<0.01). The BMD data of patients and 
controls is summarized in Table 2. The intraindividual correlation between BMD 
measurements at spine and femur of the patients showed a strong correlation in both groups 
(r=0.68-88, p<0.0001). In group 2 an inverse correlation was found between the age and LS 
BMD and t-score values (p=0.011-0.023), and between disease duration and LS BMD, z- and 
t-score values (p=0.015-0.03). No correlation was found between the laboratory markers of 
the liver disease (bilirubin, ASAT, ALAT, GGT, ALP) and BMD values at either position.  
The genotype frequency of VDR Bsm I, ER-α PvuII and XbaI is shown in table 3, the 
genotype and allele frequency of IL-1RN in patients and controls in table 4. The VDR 
genotype frequency in controls was consistent with other studies performed in healthy 
populations of Caucasian origin [13,14,15]. In osteoporotic controls the genotype frequency 
was similar to that of the healthy controls. In contrast, in PBC patients the BB genotype (n= 
19, 57.5 %, p=0.01) and B allele (n= 49, 74.2 %) was overrepresented compared to the 
control groups (p<0.01 for both).  
The IGF-I genotype and allele frequencies of PBC patients were not different from that 
of the control group (table 5). The association of BMD data and IGF-I microsatellite repeat 
polymorphism are presented in Figures 1 and 2. Patients with the IGF-I 192/192 genotype 
had higher FN z-score values than patients with other genotypes (p=0.036) despite almost 
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identical disease duration (192/192: 7.2 yrs vs. other genotypes: 6.4 yrs) and matching body 
mass index (192/192: 25.6 kg/m2, vs. other genotypes 24.9 kg/m2). The same tendency was 
observed between this genotype and LS BMD and z-score (p=0.07 for both) or FN BMD and 
t-score (p=0.058 and p=0.06) values. No difference was found in IGF-I genotype or allele 
frequencies between patients with OP (192/192=27.3%, 194/192=22.7%, other=50.0%) or 
without OP (192/192=37.5%, 194/192=31.  
 
Table 2. Bone mineral density values in lumbar spine (LS) and femoral neck (FN) of 
controls and PBC patients (BMD g/cm2, values are mean ± SD, *p≤0.01, #p=0.04 PBC 
patients vs. controls)  
 
LS FN  
BMD Z-score T-score BMD Z-score T-score 
PBC 
(n=33) 
0.937 ± 0.261 -0.68 ± 1.67 -2.01 ± 2.39 0.789± 0.227 -0.53 ± 1.68 -1.72 ± 2.20 Study 1 
Controls 
(n=82) 
1.085±  0.129* -0.16 ± 0.13 -0.95 ± 1.07* 0.901 ± 0.134* 0.05 ± 1.08# -0.66 ± 0.13* 
PBC 
(n=70) 
0.975± 0.216 -0.34 ± 1.70 -1.63± 1.98 0.831± 0.188 -0.30 ± 1.54 -1.43 ± 1.86 Study2 
Controls 
(n=139) 
1.086± 0.142* -0.05 ± 1.19 -0.89± 1.15* 0.898 ± 0.126* 0.04 ± 1.03 - 0.69± 1.06* 
 
Table 3. Genotype frequency of vitamin D-receptor BsmI, estrogen receptor alpha 
PvuII and XbaI, IGF-I microsatellite repeat and COLIA1 Sp1 polymorphism in 
controls and patients with PBC (p calculated by Chi-square analysis, # p=0.026 for SS 
vs. Ss/ss by Fischer exact test). 
 
 PBC n (%) Control n (%) p 
VDR Bsm I 
BB 19 (57.5%) 23 (28.1%) 
Bb 11 (33.3%) 41 (50.0%) 
Bb 3 (9.1 %) 18 (21.9%) 
 
p=0.01 
ER-α PvuII 
PP 6 (18.2 %) 26 (31.7%) 
Pp 25 (75.6 %) 40 (48.8%) 
pp 2 (6.2 %) 16 (19.5 %) 
 
p=0.03 
ER- α XbaI 
XX 3 (9.1 %) 15 (18.3%) 
Xx 30 (90.9%) 49 (59.8%) 
Xx 0 18 (21.9%) 
 
p=0.003 
IGF I 
192/192 53 (38.2%)  24 (34.2%)  
194/192 43 (30.9%) 20 (28.6%) 
other 43 (30.9%) 26 (37.2%) 
 
NS 
COLIA1 
SS 81 (58.4%)  51 (72.9 %) 
Ss 50 (35.9%)  16 (22.8%)  
ss 8 (5.7%)  3 (4.3%)  
 
NS 
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Table 4. Genotype and allele frequency of interleukin-1 receptor antagonist gene VNTR 
in controls and patients with PBC (NS: not significant by Chi square). Allele 4 was not 
found in either patients or controls. 
 
A IL-1RN VNTR, Genotype n (%) Allele frequency n (%)
 A1A1 A1A2 A2A2 A1A3 A2A3 A3A3 A1 A2 A3 
PBC  
(n=33) 
20 
(60.6%) 
10 
(30.2%) 
2 (6.1%) 1 (3.1%) 0 0 52 
(78.8%)
13 
(19.7%) 
1 (1.5%)
Controls 
(n=82) 
41 
(50.0%) 
28 
(34.1%) 
5  
 (6%) 
7 (8.5%) 1 (1.4%) 0 117 
(71.3%)
39 
(23.8%) 
8 
 (4.9%)
p value NS NS 
 
-2,5
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
2,5
BMD Z-score BMD Z-score BMD Z-score
192/192 (n=24) 192/194 (n=20) other (n=26)
- 2, 5
- 2
- 1, 5
- 1
- 0, 5
0
0 ,5
1
1 ,5
2
2 ,5
 
LS 
 
-2,5
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
2,5
BMD Z-score BMD Z-score BMD Z-score
192/192 (n=24) 192/194 (n=20) other (n=26)
- 2, 5
- 2
- 1, 5
- 1
- 0, 5
0
0 ,5
1
1 ,5
2
2 ,5
*p=0.036 
FN 
 
Figure 1. IGF-I microsatellite repeat genotypes, lumbar spine (LS) and left femur neck (FN) BMD and 
z-scores in patients with PBC (BMD=g/cm2, values are mean ± SD, *p=0.036 for Z-score values 
192/192 vs. others by Mann Whitney U test). 
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The IL-1RN genotype frequency of the osteoporotic controls was similar to the healthy 
subjects and it was not different from that of the PBC patients. 25%, other=31.25%). The 
COLIA1 Sp1 genotype frequency of PBC patients was also not different from that of the 
controls (Hardy-Weinberg disequlibrium test). The s allele was less frequent in PBC patients 
without OP than in controls (12.5% vs. 24.5%, p=0.01 by Fischer exact). The same tendency 
was observed between patients with and without OP (22.7% vs. 12.5%, p=0.08) (see table 6 
and Figure 2).  
 
Table 5.: Allele frequency of IGF-I microsatellite repeat polymorphisms in controls and 
patients with PBC (NS: not significant by Chi square). 
 
B IGF-I n (%) 
 174 176 188 190 192 194 196 198 200 
Controls 
(n=278) 
2 
(0.7%) 
1 
(0.3%) 
2 
(0.7%) 
15 
(5.4%) 
185 
(66.5%)
51 
(18.3%)
17 
(6.2%) 
4 
(1.6%) 
1 
(0.3%) 
PBC (n=140) 0 1 
(0.7%) 
3 
(2.1%) 
12 
(8.6%) 
84 
(60.0%)
26 
(18.6%)
13 
(9.3%) 
0 1 
(0.7%) 
P value NS 
 
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
BMD Z-score BMD Z-score
                             SS                   
(n=51)
                         Ss/ss                   
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Figure 2. COLIA1 Sp1 genotypes, lumbar spine BMD and z-scores in patients with PBC (BMD=g/cm2, 
values are mean ± SD. No significant difference between SS and Ss/ss by Mann-Whitney U test). 
No association was found between BMD (t and z scores) and the other polymorphisms 
determined (VDR, ER-alpha PvuII or XbaI, IL-1RN or COLIA1 Sp1). There was a tendency 
of VDR BsmI bb genotype to be associated with higher BMD values however, but only 3 
patients had this genotype.  
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Table 6. Genotype frequency the vitamin D-receptor (VDR) BsmI, estrogen receptor 
alpha (ER-α) PvuII and XbaI and IGF-I microsatellite repeat polymorphism and 
COLIA1 Sp1 polymorphism in PBC patients with and without osteoporosis. 
 
 with osteoporosis n (%) without osteoporosis n (%) p 
VDR Bsm I 
BB 9 (64%) 10 (53%) 
Bb 5 (36%) 6 (32%) 
Bb 0 3 (15%) 
 
NS 
ER-α PvuII 
PP 1 (8%) 4 (21%) 
Pp 11 (78%) 15 (79%) 
pp 2 (14%) 0 
 
NS 
ER-α XbaI 
XX 2 (14%) 1 (6%) 
Xx 12 (85%) 18 (94%) 
Xx 0 0 
 
NS 
IGF I 
192/192 6 (27.3%)  18 (37.5%)  
194/192 5 (22.7%) 15 (31.2%) 
other 11 (50.0%) 15 (31.2%) 
 
NS 
COLIA1 
SS 14 (63.6%)  37 (77.1%)  
Ss 6 (27.3%) 10 (20.8%) 
ss 2 (9.1%) 1 (2.1%) 
 
NS 
 
 
DISCUSSION 
 
This study attempted to identify genetic markers for PBC and for PBC-associated hepatic 
osteopathy. Among many markers investigated only the BB genotype of the VDR and the 
XbaI Xx genotype of the ER-α ware overrepresented in middle-aged Hungarian PBC patients 
as compared with both healthy subjects and disease controls with non-liver disease-related 
osteoporosis. However, we did not find a direct association between VDR genotypes and 
BMD [56]. 
Osteoporosis is a common disorder in PBC [2,3]. Its prevalence in this study (31-42%) is 
in concordance with previously reported values of 24-43 % [2,7,57]. The cause of bone 
abnormalities in patients with cholestatic liver disease is not fully understood. Disease 
duration may reflect severity of the disease; however the rate of progression is variable. As 
expected [1-2,21] patients with osteoporosis were older and had a longer disease duration 
than those without osteoporosis. Both high and low bone turnover has been reported [8-10]. 
High turnover osteoporosis is further supported by the elevated CTX-I level found in group 2, 
particularly in advanced stages. In these patients OC levels were also elevated indicating 
increased osteoblastic activity representing a possible compensatory mechanism. An 
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association between the rate of bone loss and the severity of cholestasis has been reported in 
PBC patients [22,58], but was not confirmed in this study. This discrepancy may be 
explained by the fact that all of our patients were treated with UDCA [59], which improved 
cholestasis.  
Many studies have addressed the genetic background of osteopenia and osteoporosis, 
several candidate genes have been investigated (VDR, ER-α, IL-6, collagen 1A1) [13-54]. 
VDR has been of special interest [13-17]. 
Similarly, a possible genetic background of PBC is under intense investigation. 
Associations were found at chromosomes 6p21.3 and 2q including HLA DRBI*08, 
CTLA4*G, IL1RN-IL1B haplotypes, CASP8 and APO-E epsilon4 [60,61]. Recently the 
HLA-DRB1*11 has been shown to be associated with reduced risk of developing PBC, while 
the presence of B*15, B*41, B*55 and B*58 was found to be more frequent in PBC [62].  
The study of the role of genetic polymorphisms of bone formation in patients with PBC 
is complicated because they may be independently associated with PBC like the BsmI 
polymorphism of VDR or the Sp1 polymorphism in COLIA1 gene [20,22,63]. Furthermore, 
the possible genetic factor may render subjects more susceptible to the effects of 
pathophysiologic mechanisms which by themselves are involved in the pathogenesis of bone 
disease.  
This problem is further complicated by the fact, that established risk factors for 
osteoporosis are also associated with the development of autoimmune diseases such as PBC. 
1,25-(OH)2-D3 was shown to inhibit T-cell activation in vitro and in vivo, and to suppress 
IL-1, IL-2, IL-6, TNF and INF-γ production [64]. These cytokines are important in the 
development of T helper 1 cells, which are believed to be involved in the pathogenesis of 
autoimmune diseases, such as PBC. It has also been shown that vitamin D is able to regulate 
the expression of costimulatory molecules B7.1 and B7.2 [65]. Interestingly VDR genotypes 
have been found to be associated with susceptibility to various diseases, as Graves’ disease 
[66,67] and hepatitis B [68]. The association between the presence of B allele or BB 
genotype and the susceptibility to other autoimmune diseases (like Graves’ disease) suggests 
that VDR-polymorphisms may not only be associated with osteoporosis, but may also play a 
role in the development of autoimmune diseases. Not surprisingly, the reported data in PBC 
patients are conflicting [20,21,22]. A similar association may apply to ER-α and IL-1ra. ER-
α is a strong candidate for the regulation of BMD [17, 30-33], but ER-α and β expression 
was also reported in peripheral and thymic lymphocytes, macrophages and endothelial cells, 
suggesting that estrogen might affect immune cells during development and mature function 
[69]. Furthermore in T cells from female patients with systemic lupus erythematosus an 
altered ER function was identified [70]. In autoimmune conditions and in multiple sclerosis 
ER-α P allele and Xx was associated with disease susceptibility and onset of the disease [71]. 
We also found an overrepresentation of the Pp and Xx genotypes in PBC patients.  
IL-1 is a potent stimulator of the bone resorption, and it has been implicated in the 
pathogenesis of postmenopausal osteoporosis [45,46]. Interleukin-1 antagonist protein (IL-
1ra) is a natural anti-inflammatory molecule, a competitive inhibitor of IL-1α and β. In 
Graves disease, polymyositis, systemic lupus erythematosus and rheumatoid arthritis elevated 
levels of IL-1ra have been reported [48]. Increased frequency of A2 allele was found in 
inflammatory and autoimmune diseases (Graves’s disease, inflammatory bowel disease, 
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multiple sclerosis, Henoch-Schönlein nephritis, etc.) [48-51]. In vitro in the presence of A2 
allele a reduced IL-1/IL-1ra ratio with increased IL-1ra production was reported [72]. 
Donaldson et al. found IL-1RN VNTR A1A1 genotype (60% vs. 40%, OR: 2.28) and the IL-
1B 1,1 genotype (65% vs. 43%, OR: 2.37) to be more frequent in PBC compared to controls 
[73]. We observed a similar but not significant tendency in our PBC patients. The A1A1 
genotype is not associated with reduced IL-1/IL-1Ra ratio, in concordance with the observed 
proinflammatory T-cell (T helper 1) profile in PBC [74]. In our study we did not find any 
significant difference in BMD in patients having at least one A2 allele compared to non-
carriers. The presence of A2 allele was not more frequent in the non-osteoporotic patients nor 
we did find any correlation between IL-1RN genotype and BMD. Our results suggest that IL-
1RN VNTR polymorphism may not play an essential role in the development of osteopenia 
in PBC, at least not in this set of patients.  
Because of its important role in the acquisition of peak BMD, modeling of bone and 
stimulation of periosteal bone growth [39,75] several studies addressed the association 
between IGF-I microsatellite polymorphism and OP [39,53]. Liver derived IGF-I [75] exert a 
small, but significant effect on cortical periosteal bone growth and on adult axial skeletal 
growth. This may be affected by chronic liver diseases. Low serum IGF-I has been reported 
in chronic liver diseases [41,42], but no relationship was found between serum IGF-I and 
BMD [42]. In contrast, IGF-I treatment restored osteopenia in experimental cirrhosis [76]. In 
our study the 192/192 genotype was associated with higher femoral neck z-scores compared 
to other genotypes, which raises the possibility that IGF-I microsatellite repeat polymorphism 
together with genetic and/or environmental factors is involved in the complex regulation of 
BMD in PBC. To our knowledge this is the first report on IGF-I polymorphism in chronic 
liver diseases including PBC. However, in the absence in differences in genotype frequencies 
between patients and controls, it is unlikely that IGF-I microsatellite polymorphism plays an 
essential role in the pathogenesis and/or progression of PBC. 
Even more complex is the relation of genetic marker with the pathogenesis and the 
progression of PBC. The pathogenesis of PBC is unknown, but because of the presence of 
typical autoantibodies it is generally considered as an autoimmune disease. Thus, the relation 
of some of the genetic polymorphisms to autoimmunity is of interest. Based on our data a 
direct relation of the investigated polymorphisms and the pathogenesis of PBC seems 
unlikely. However, it may be assumed, that genetic factors influence the rapidity of 
progression to cirrhosis.  
Insulin-like growth factor-I (IGF-I) is involved in the regulation of cell growth and 
differentiation; it stimulates linear growth [38]. An important issue is that IGF-I treatment has 
been found to exert an antifibrogenic effect in experimental setting [77]. The treatment of 
cirrhotic rats was accompanied by the reduction hydroxyproline content, prolyl hydroxylase 
activity, collagen 1alphaI and 1alpha (III) m RNA expression in the liver. Furthermore IGF-I 
treatment partially normalized the gene expression profile and restored the expression of 
growth hormone receptor and the levels of global DNA methylation in experimental 
cirrhosis, and also enhanced the regenerative activity [78]. Low serum IGF-I has been 
reported in chronic liver diseases [40,41,42], however, the role of IGF-I protein in 
fibrogenesis is complex. 
Peter Laszlo Lakatos, Eva Bajnok, Claudia Willheim-Polli et al. 72 
Collagen type I plays an important role in liver fibrogenesis. Early fibrotic events lead to 
conversion of the basement membrane-like matrix to one rich in fibrillar matrix, with 
dramatic increase in the expression of type I collagen [79]. Mutations in collagen type I that 
confers resistance to the action collagenases critically impair hepatic stellate cell apoptosis 
and may prevent restoration of hepatocyte mass in liver fibrosis [80], furthermore 
halofuginone, a collagen type I inhibitor was found to improve liver regeneration in 
experimental cirrhosis [81]. Since collagen type I expression is influenced by Sp1 
polymorphism and lower frequency of the s allele was found in PBC, it might be 
hypothesized that COLIA1 may influence disease progression and fibrogenesis in patients 
with PBC. 
It has also been suggested that IL-1RN polymorphism might influence the risk of hepatic 
fibrosis. In Japanese alcoholics heterozygotes for A1 allele rather than A1 homozygotes 
tended to have greater risk to develop fibrosis or cirrhosis [82]. Although numbers are small, 
in our study 7 out of 11 (63.3 %) patients heterozygous for A1 had advanced stage disease 
(stage III-IV), while 8 out of 22 (36.4%) of the A1 or A2 homozygotes, however, they did not 
differ in age nor had a longer disease history. Further studies are needed to determine, 
whether IL-1RN VNTR polymorphism could be associated with a more rapid disease 
progression.  
In summary, in our studies we confirmed previous findings on higher frequency of the 
VDR BsmI BB genotype and B allele in patients with PBC. Our study was the first study to 
our knowledge to report on the ER-α XbaI and PvuII polymorphisms in PBC patients. An 
overrepresentation of the ER-α Pp and Xx genotypes was found in Hungarian PBC patients, 
while there was no difference in the IL-1RN VNTR and IGF I microsatellite repeat 
polymorphism between PBC patients and controls. Since IGF-I polymorphism was associated 
to BMD in PBC, it may be hypothesized that not COLIA1 but IGF-I together with other 
genetic and environmental factors may be involved in the complex regulation of BMD in 
PBC. In contrast to previous studies the s allele was less frequent in patients with PBC, and 
its presence was not associated with BMD.  
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